Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma

Blood

Volumn 119, Issue 8, 2012, Pages 1882-1887

  Klapper, Wolfram ^a   Kreuz, Markus ^b   Kohler, Christian W ^c   Burkhardt, Birgit ^d   Szczepanowski, Monika ^a   Salaverria, Itziar ^a   Hummel, Michael ^e   Loeffler, Markus ^b   Pellissery, Shoji ^a   Woessmann, Wilhelm ^d   Schwänen, Carsten ^f   Trümper, Lorenz ^g   Wessendorf, Swen ^f   Spang, Rainer ^c   Hasenclever, Dirk ^b   Siebert, Reiner ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY HOSPITAL ULM   (Germany)

^g UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2;

ADOLESCENT; ADULT; AGE; ARTICLE; B CELL LYMPHOMA; CANCER PROGNOSIS; CHILD; CHROMOSOME TRANSLOCATION; CYTOGENETICS; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 84857592849     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-388470     Document Type: Article

References (34)

1. Swerdlow SH, Campo E, Harris N, et al. WHO Classification of Tumors of the Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008.
2. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8(1):68-74. (Pubitemid 34101731)
3. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-1947. (Pubitemid 34651353)
4. Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
5. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006; 354(23):2419-2430. (Pubitemid 43855045)
6. Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a populationbased study. J Clin Oncol. 1996;14(7):2131-2138. (Pubitemid 26230116)
7. Klapper W, Stoecklein H, Zeynalova S, et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Leukemia. 2008;22(12):2226-2229.
8. Savage KJ, Johnson NA, Ben Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533-3537.
9. Copie-Bergman C, Gaulard P, Leroy K, et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large Bcell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol. 2009;27(33):5573-5579.
10. Offit K, Wong G, Filippa DA, Tao Y, Chaganti RS. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations. Blood. 1991;77(7):1508-1515.
11. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-994.
12. Reiter A, Klapper W. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. Br J Haematol. 2008;142(3):329-347. (Pubitemid 351962165)
13. Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM group study NHL-BFM95. Blood. 2004; 105(3):948-958. (Pubitemid 40170860)
14. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242. (Pubitemid 34438862)
15. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the Mab- Thera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379-391.
16. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999;94(10):3294-3306. (Pubitemid 29536122)
17. Patte C, Auperin A, Michon J, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97(11):3370-3379.
18. Oschlies I, Klapper W, Zimmermann M, et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood. 2006; 107(10):4047-4052. (Pubitemid 43726813)
19. Klapper W, Szczepanowski M, Burkhardt B, et al. Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. Blood. 2008;112(4):1374-1381.
20. Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131(1):39-49. (Pubitemid 43899706)
21. Salaverria I, Philipp C, Oschlies I, et al. Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood. 2011;118(1):139-147.
22. de Jong D, Xie W, Rosenwald A, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol. 2009;62(2): 128-138.
23. Bentink S, Wessendorf S, Schwaenen C, et al. Pathway activation patterns in diffuse large B-cell lymphomas. Leukemia. 2008;22(9):1746-1754.
24. Fiegler H, Carr P, Douglas EJ, et al. DNA microarrays for comparative genomic hybridization based on DOP-PCR amplification of BAC and PAC clones. Genes Chromosomes Cancer. 2003; 36(4):361-374. (Pubitemid 36314519)
25. Schwaenen C, Nessling M, Wessendorf S, et al. Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci U S A. 2004; 101(4):1039-1044. (Pubitemid 38160580)
26. Kreuz M, Rosolowski M, Berger H, et al. Development and implementation of an analysis tool for array-based comparative genomic hybridization. Methods Inf Med. 2007;46(5):608-613. (Pubitemid 47598982)
27. Ventura RA, Martin-Subero JI, Jones M, et al. FISH analysis for the detection of lymphomaassociated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn. 2006; 8(2):141-151. (Pubitemid 43811236)
28. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2):181-185.
29. Miles RR, Raphael M, McCarthy K, et al. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: report of the French-American-British (FAB) international study group. Pediatr Blood Cancer. 2008;51(3):369-374.
30. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008;105(36):13520-13525.
31. Szczepanski T, Harrison CJ, van Dongen JJ. Genetic aberrations in paediatric acute leukaemias and implications for management of patients. Lancet Oncol. 2010;11(9):880-889.
32. Oschlies I, Salaverria I, Mahn F, et al. Pediatric follicular lymphoma: a clinico-pathological study of a population-based series of patients treated within the NHL-BFM (Berlin-Frankfurt-Munster) multicenter trials. Haematologica. 2010;95(2): 253-259.
33. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373-2380.
34. Thunberg U, Amini RM, Linderoth J, Roos G, Enblad G, Berglund M. BCL2 expression in de novo diffuse large B-cell lymphoma partly reflects normal differences in age distribution. Br J Haematol. 2009;146(6):683-684.